Public Market Listing
Live quotes, historical charts, and market capitalization for Sihuan Pharmaceutical Holdings are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
janagliflozin(Huiyoujing) | Phase 3 | SGLT2Small molecule | Type 2 DiabetesChronic Kidney Disease |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (1)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-H1 | $158M | $21M | $455M | — | report ↗ |
Sihuan Pharmaceutical Holdings reported revenue of $158.16M, R&D spend of $21.08M, and cash and equivalents of $454.72M for H1 2025.
Figures only: this period's report disclosed no narrative text
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $364M | $41M | $509M | — | report ↗ |